Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19083361 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | March 2025 | January 2026 | Allow | 10 | 1 | 1 | Yes | No |
| 18730678 | METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS | July 2024 | August 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18393974 | ADAPTER FOR USE IN A PLANETARY MIXER | December 2023 | April 2025 | Allow | 16 | 3 | 0 | No | No |
| 18501446 | ADAPTER FOR USE IN A PLANETARY MIXER | November 2023 | August 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18446687 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | August 2023 | September 2025 | Allow | 25 | 1 | 0 | No | No |
| 18231955 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOF | August 2023 | January 2026 | Abandon | 29 | 1 | 0 | No | No |
| 18208658 | ACTIVATED CARBON PHARMACEUTICAL COMPOSITIONS | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18195307 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | May 2023 | November 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18143944 | IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE | May 2023 | March 2026 | Allow | 34 | 7 | 0 | Yes | No |
| 18140646 | Topical preparations comprising biodegradable polyalkoxylated polyols polyester | April 2023 | September 2025 | Allow | 28 | 4 | 1 | Yes | No |
| 18295906 | MEDICAMENT-CONTAINING HOLLOW PARTICLE | April 2023 | August 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18130771 | TOPICAL COMPOSITION FOR TREATING DANDRUFF AND SEBORRHEIC DERMATITIS OF A SCALP | April 2023 | March 2026 | Abandon | 35 | 2 | 0 | No | Yes |
| 18121883 | METHODS FOR ADMINISTERING ARIPIPRAZOLE | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18177011 | METHODS FOR FIXING HAIR AND SKIN | March 2023 | February 2026 | Abandon | 35 | 5 | 1 | Yes | Yes |
| 18108368 | PERGULARIA TOMENTOSA SILVER NANOPARTICLES | February 2023 | April 2025 | Abandon | 26 | 4 | 1 | No | No |
| 18156432 | SOLID LIPID NANOPARTICLE FOR INTRACELLULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD FOR PRODUCTION THE SAME | January 2023 | May 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18096869 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION | January 2023 | November 2025 | Abandon | 34 | 2 | 1 | No | No |
| 18092517 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENT | January 2023 | September 2024 | Allow | 20 | 3 | 1 | Yes | No |
| 18003609 | METHOD FOR DIAGNOSING DOWN'S SYNDROME BY USING DOWN'S SYNDROME-SPECIFIC EPIGENETIC MARKER | December 2022 | February 2026 | Abandon | 38 | 4 | 1 | Yes | No |
| 18067541 | FORTIFIED MICRONUTRIENT SALT FORMULATIONS | December 2022 | May 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18076023 | IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE | December 2022 | March 2026 | Allow | 39 | 6 | 0 | Yes | No |
| 18058513 | MODIFIED GENE VACCINES AGAINST AVIAN CORONAVIRUSES AND METHODS OF USING THE SAME | November 2022 | March 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17992783 | CARBON DOTS FOR DIAGNOSTIC ANALYSIS AND DRUG DELIVERY | November 2022 | June 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18053865 | RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA | November 2022 | June 2025 | Allow | 31 | 3 | 1 | No | No |
| 17915569 | NUCLEIC ACIDS ENCODING HUMAN FUS PROTEIN AND USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17933937 | AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM | September 2022 | February 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17941675 | METHODS FOR FIXING HAIR AND SKIN | September 2022 | December 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17884187 | METHODS AND CONTROL COMPOSITIONS FOR A QUANTITATIVE POLYMERASE CHAIN REACTION | August 2022 | December 2025 | Allow | 40 | 2 | 0 | No | No |
| 17816456 | BIODEGRADABLE HYDROGEL AND METHODS FOR USE THEREOF | August 2022 | July 2025 | Abandon | 36 | 3 | 1 | Yes | No |
| 17854139 | COLLAGEN-BASED THERAPEUTIC DELIVERY SYSTEMS | June 2022 | December 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17836067 | METHODS FOR MAKING COMPOSITIONS FOR PULMONARY ADMINISTRATION | June 2022 | October 2024 | Allow | 28 | 1 | 1 | No | No |
| 17771808 | OVERLAPPING THERAPEUTIC STRATEGIES FOR CYSTINOSIS TREATMENT AND COSMETIC SKIN DARKENING | April 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17640764 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | March 2022 | November 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17680295 | COMPOSITIONS AND METHODS FOR INHIBITING TCF/LEF TRANSCRIPTIONAL ACTIVITY | February 2022 | February 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17675674 | DRUG TREATMENT AND BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | February 2022 | August 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17633478 | METHOD FOR PRODUCING NUCLEIC ACID MOLECULE | February 2022 | December 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17591485 | LIPOPOLYSACCHARIDE (LPS) APTAMERS AND ASSOCIATED METHODS | February 2022 | December 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17589223 | NANODRUG PARTICLES, THE USE THEREOF, AND PREPARATION METHOD THEREOF | January 2022 | September 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17587743 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | January 2022 | December 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17631216 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS | January 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17564399 | METHODS FOR MAKING ANTIFOULING MATERIALS | December 2021 | December 2024 | Allow | 36 | 3 | 1 | Yes | No |
| 17564405 | ANTIFOULING MATERIALS | December 2021 | December 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17620879 | A PHARMACEUTICAL COMPOSITION OF S1PR MODULATORS | December 2021 | March 2025 | Allow | 39 | 0 | 0 | No | No |
| 17644986 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | December 2021 | December 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17616760 | COMPOSITIONS AND METHODS RELATING TO ERYTHROCYTES WITH ADHERED PARTICLES | December 2021 | February 2026 | Allow | 50 | 2 | 1 | Yes | Yes |
| 17616800 | COMPOSITIONS AND METHODS FOR IMPROVING PLANT HEALTH AND CONTROLLING PLANT DISEASE | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17542112 | METHODS FOR TREATING RELAXED HAIR | December 2021 | June 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17538733 | ENHANCED PERFORMANCE SOLUTION FOR TISSUE GRAFTS | November 2021 | March 2025 | Abandon | 39 | 4 | 1 | No | No |
| 17615152 | SOLID DISPERSION AND PREPARATION METHOD THEREFOR | November 2021 | August 2025 | Abandon | 45 | 4 | 1 | No | No |
| 17595584 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | November 2021 | October 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17595620 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | November 2021 | January 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17612912 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | November 2021 | August 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17525521 | PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID, METHOD FOR MANUFACTURING PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID, AND PARTICULATE POLY(LACTIC-CO-GLYCOLIC) ACID MANUFACTURING APPARATUS | November 2021 | December 2024 | Allow | 37 | 4 | 0 | Yes | No |
| 17482143 | HYDROGEL-ENCAPSULATED BETA CELLS, BETA-CELL ENCAPSULATION PROCESS, AND USES THEREOF | September 2021 | December 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17439159 | NOVEL NUCLEIC ACID MODIFIERS | September 2021 | November 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17473676 | METHODS OF TREATING MENTAL DISORDERS | September 2021 | December 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17471878 | MIXED MATERIAL IMPLANTS INCORPORATING ADDITIVES | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17406609 | KERATIN TREATMENT FORMULATIONS AND METHODS | August 2021 | April 2025 | Abandon | 43 | 2 | 1 | No | Yes |
| 17365361 | MODIFIED NUCLEOTIDES AND USES THEREOF | July 2021 | September 2025 | Allow | 51 | 1 | 2 | No | No |
| 17362397 | COLOR COATINGS WITH DOWNSTREAM FEATURES | June 2021 | March 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17359137 | AUXIN HERBICIDE AND L-GLUFOSINATE MIXTURES | June 2021 | July 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17358929 | SYNTHETIC ANTIMICROBIAL MINERAL COMPOSITIONS, METHODS OF MAKING AND USING SAME | June 2021 | August 2024 | Allow | 38 | 2 | 1 | No | No |
| 17357119 | DISSOLVABLE SOLID FIBROUS ARTICLES CONTAINING ANIONIC SURFACTANTS | June 2021 | June 2025 | Abandon | 47 | 5 | 1 | No | No |
| 17340405 | OSTEOGENIC BIOMATERIAL | June 2021 | October 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17311211 | REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLS | June 2021 | March 2026 | Abandon | 58 | 2 | 1 | Yes | No |
| 17298326 | USE OF CATIONIC HYDROXYALKYL GUARS FOR MICROORGANISMS GROWTH | May 2021 | July 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17317335 | COMPOSITIONS OF POLYMERIC MICRODEVICES AND METHODS OF USE THEREOF IN CANCER IMMUNOTHERAPY | May 2021 | April 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17243113 | AEROSOL SPRAYER FOR INSECT PEST MATING DISRUPTION | April 2021 | October 2024 | Allow | 42 | 2 | 0 | No | No |
| 17223641 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | April 2021 | December 2024 | Abandon | 44 | 3 | 1 | No | No |
| 17281014 | INJECTABLE HYDROGELS FOR CONTROLLED RELEASE OF IMMUNOMODULATORY COMPOUNDS | March 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17256387 | Hyaluronic Acid-Based Zwitterionic Polymer Brush, Preparation Method Thereof, and Use Thereof | December 2020 | January 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17105587 | Composition of corneal implantation, and the use and preparation method thereof | November 2020 | October 2024 | Abandon | 46 | 3 | 1 | No | No |
| 17054137 | NOVEL CROP NUTRITION AND FORTIFICATION COMPOSITION | November 2020 | July 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17049776 | TRANSITION METAL ORGANIC FRAMEWORK HAVING ANTIBACTERIAL PROPERTIES | October 2020 | October 2025 | Abandon | 60 | 3 | 1 | No | No |
| 17035339 | COMPOSITIONS AND METHODS FOR TARGETING CELLS | September 2020 | July 2024 | Allow | 46 | 4 | 1 | Yes | No |
| 17024755 | Horticulture Additive | September 2020 | May 2025 | Abandon | 55 | 4 | 1 | No | No |
| 16999841 | RADIOPAQUE MULTI-ARMED POLYMERS AND COMPOSITIONS, SYSTEMS AND METHODS PERTAINING TO THE SAME | August 2020 | January 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 15733436 | NOVEL ANTHRANILAMIDES, THEIR USE AS INSECTICIDE AND PROCESSES FOR PREPARING THE SAME | July 2020 | October 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16920341 | PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES | July 2020 | August 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16447716 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | June 2019 | October 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16427560 | RESIDENT ARTICLES FOR GRAM-LEVEL DOSING | May 2019 | April 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 15769710 | CANCER VACCINES | April 2018 | November 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15838977 | METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTION | December 2017 | April 2019 | Allow | 16 | 1 | 1 | Yes | No |
| 15570276 | ANTIBACTERIAL NANOFIBRES | October 2017 | July 2020 | Abandon | 33 | 9 | 1 | No | No |
| 15542793 | COSMETIC COMPOSITION FOR ORAL ADMINISTRATION FOR REINFORCING THE SKIN BARRIER | July 2017 | September 2018 | Allow | 14 | 3 | 0 | Yes | No |
| 15582076 | HAIR-TREATMENT COMPOSITIONS COMPRISING A POLYURETHANE LATEX POLYMER AND CATIONIC COMPOUND | April 2017 | May 2025 | Allow | 60 | 10 | 1 | Yes | Yes |
| 15492146 | METHOD FOR MAKING A TRANSDERMAL FENTANYL PATCH WITH EVEN DRUG CRYSTAL DISTRIBUTION | April 2017 | April 2019 | Allow | 24 | 2 | 1 | Yes | No |
| 15483006 | ANTIBACTERIAL SPECTACLE PART AND ANTIBACTERIAL TREAMENT METHOD | April 2017 | July 2018 | Allow | 15 | 2 | 1 | Yes | No |
| 15393850 | 6-ACYL-1,2,4-TRIAZINE-3,5-DIONE DERIVATIVE AND HERBICIDES | December 2016 | May 2018 | Allow | 16 | 2 | 1 | No | No |
| 15322776 | Antitumor Composition Based on Hyaluronic Acid and Inorganic Nanoparticles, Method of Preparation Thereof and Use Thereof | December 2016 | February 2020 | Allow | 37 | 4 | 1 | Yes | No |
| 15361426 | CRYSTALLINE COATING AND RELEASE OF BIOACTIVE AGENTS | November 2016 | July 2018 | Allow | 20 | 2 | 1 | Yes | No |
| 15079171 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | March 2016 | January 2018 | Allow | 22 | 3 | 0 | Yes | No |
| 14919962 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF | October 2015 | August 2017 | Allow | 22 | 1 | 0 | Yes | No |
| 14776827 | METHODS OF IDENTIFICATION AND USE OF NEMATICIDE COMPOUNDS | September 2015 | September 2019 | Allow | 48 | 2 | 1 | Yes | No |
| 14756288 | Acne formulation having stabilized ascorbic acid and other actives | August 2015 | May 2017 | Allow | 21 | 1 | 0 | Yes | No |
| 14762286 | AGROCHEMICAL COMPOSITION, METHOD FOR ITS PREPARATION AND USE THEREOF | July 2015 | September 2019 | Allow | 50 | 6 | 1 | Yes | No |
| 14742936 | PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME | June 2015 | June 2017 | Allow | 24 | 1 | 1 | Yes | No |
| 14702843 | Method for Oxygen Treatment of Intact Skin | May 2015 | October 2016 | Allow | 17 | 1 | 0 | Yes | No |
| 14667826 | ABUSE DETERRENT IMMEDIATE RELEASE BIPHASIC MATRIX SOLID DOSAGE FORM | March 2015 | December 2016 | Allow | 21 | 2 | 0 | Yes | No |
| 14427846 | A SOFT GELATIN ENCAPSULATED PHARMACEUTICAL COMPOSITION OF CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID IN FREE ACID FORM AND CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID IN FREE ACID FORM | March 2015 | March 2019 | Allow | 48 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VANHORN, ABIGAIL LOUISE.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VANHORN, ABIGAIL LOUISE works in Art Unit 1636 and has examined 142 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner VANHORN, ABIGAIL LOUISE's allowance rate of 85.2% places them in the 62% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by VANHORN, ABIGAIL LOUISE receive 3.25 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VANHORN, ABIGAIL LOUISE is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.9% benefit to allowance rate for applications examined by VANHORN, ABIGAIL LOUISE. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.8% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 76.0% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 52.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.9% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.0% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.